Blood Cancers Today Staff WritersMyeloma | March 15, 2024
The FDA Oncologic Drugs Advisory Committee (ODAC) voted on whether the risk-benefit assessment for cilta-cel is sufficient evidence to recommend the approval of a supplemental Biologics License Application for an updated indication.